Jyke Pharmaceutical Private Limited - Due diligence report

A 360° intelligence report on Jyke Pharmaceutical Private Limited: trust score, financial health, credit view, compliance, directors, growth…

2011-12-12 Gwalior, Madhya Pradesh Active Unlisted Active Compliant
Share
Connect MCP
JP Jyke Pharmaceutical Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Jyke Pharmaceutical Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
88/100
Trust Score
Low Risk

Jyke Pharmaceutical Private Limited is assessed as Low Risk with a Trust Score of 88/100. Jyke Pharmaceutical Private Limited is an active private limited indian non-government company incorporated in 2011, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 05 Oct 2026 from the latest processed filings. Jyke Pharmaceutical Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
88/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 3 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (15.13 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited1 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
JAI PRAKASH MATHUR 01234567 Director 01/04/2018 6 yrs Approved
SATYENDRA KUMAR JAIN 01234567 Director 01/04/2018 6 yrs Approved
SAHIL MATHUR 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 80 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 2 year(s).
Profit expanded 2.1x year-on-year.
Operating for 14+ years.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence89/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment68/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 15.13 Lakh already registered.
  • Compliance record supports lending.
Investor view82/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 9 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
29 Oct 2022
Charge created
Hdfc Bank Limited - 15.13 Lakh
30 Nov 2016
Director appointed
SATYENDRA KUMAR JAIN (Director)
Director ceased
NEHA MATHUR
21 Jan 2012
Director ceased
SATYENDRA KUMAR JAIN
12 Dec 2011
Incorporated
Registered with Roc Gwalior
Director appointed
JAI PRAKASH MATHUR (Director)
Director appointed
SAHIL MATHUR (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 2 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2017 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Ecosure Pharma Private Limited U24232DL2011PTC217405 New Delhi, Delhi, India
Basil Drugs Private Limited U24232MP2001PTC014624 Indore, Madhya Pradesh, India
Sm Drugs Private Limited U51101TN2013PTC094223 Madurai, Tamil Nadu, India
Petacom U74900DL2015PTC286209 New Delhi, Delhi, India
Rhythm Pharma India Private Limited U51397TZ2009PTC015095 Salem, Tamil Nadu, India
Meditex Pharma Pvt Ltd U24239HR1962PTC002419 Gurgaon Haryana, Haryana, India
Bonnevie Pharma Private Limited U24239MH2008PTC184631 Mumbai, Maharashtra, India
Solvmax Lifesciences Private Limited U24232BR2011PTC016723 Patna, Bihar, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Jyke Pharmaceutical Private Limited before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Jyke Pharmaceutical Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Jyke Pharmaceutical Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 88/100, distress signals and MSME payment-delay disclosures - know whether Jyke Pharmaceutical Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Jyke Pharmaceutical Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Jyke Pharmaceutical Private Limited an active company?

Jyke Pharmaceutical Private Limited has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Jyke Pharmaceutical Private Limited financially healthy?

Jyke Pharmaceutical Private Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Jyke Pharmaceutical Private Limited?

Its overall Trust Score is 88/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Jyke Pharmaceutical Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Jyke Pharmaceutical Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Jyke Pharmaceutical Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2025). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Jyke Pharmaceutical Private Limited?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.